Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma Mar

AstraZeneca AZ

AZ, Amgen’s first-in-class asthma drug gets breakthrough status

Clinical data from the TSLP targeting antibody is due in 2020

- PMLiVE

Daily Brief: Blincyto another option in ALL alongside Kymriah, AZ approval for Bydureon

European approvals for Amgen and AstraZeneca

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

- PMLiVE

ViiV chalks up another win for two-drug HIV regimen

Once a month injection matches triple oral therapy

- PMLiVE

Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

Three new biosimilars also gets the green light

- PMLiVE

Amgen’s R&D chief Sean Harper retires to seek biotech post

Adds to trend in senior leaders

- PMLiVE

GSK two-drug trial in untreated HIV raises Gilead rivalry

Intends to file the combination later this year to challenge Gilead’s Biktarvy

- PMLiVE

Daily Brief: Janssen’s HIV vaccine, Q2 results, Biogen’s Alzheimer’s data

News from pharma, biotech and healthcare

- PMLiVE

Trial data suggest Abivax’ drug may clear latent HIV

The drug reduced HIV DNA in cells over 28 days

- PMLiVE

90TEN celebrates double win for HIV campaign at Communiqué 2018

Agency wins two awards for bold My Journey: Flight HIV101 campaign

- PMLiVE

Daily Brief: Europe changes mind on Puma drug, Pfizer’s Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest

The latest from pharma, biotech and healthcare

Gilead Sciences

Gilead’s Biktarvy gets European approval, setting up battle with GSK

The drug could offset Gilead's disappointing hep C franchise

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links